Merck

Merck Launches Oncology Network, Reduces Sites

Thursday, June 17, 2010 09:14 AM

In an effort to streamline its cancer research, Merck has launched the Merck Oncology Collaborative Trials Network, a collection of key oncology-focused investigative sites around the world with which Merck will work exclusively on promising compounds during early phases.

More... »

Clinical Trial Activity in Russia Dipped in 2009

Friday, March 5, 2010 06:56 AM

According to Russia-based contract research organization (CRO) Synergy Research Group’s Annual Orange Report, Russia’s regulatory agency Federal Service on Surveillance in Healthcare and Social Development of the Russian Federation (RosZdravNadzor, RZN) approved 577 new clinical trials during 2009, 6% fewer than in 2008. Sixty percent, or 348 of the new studies, were multinational multi-center trials, down 4% from 2008.

More... »

Merck Serono Building Global R&D Center in Beijing

Thursday, December 10, 2009 07:49 AM

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, wants to strengthen its global research and development (R&D) capabilities by establishing a global R&D center in Beijing, China.

More... »

Phase Forward Receives SCDM Award

Friday, October 23, 2009 07:13 AM

The Society for Clinical Data Management has awarded its annual Data Driven Innovation Award to Phase Forward for developing a technology that increased external data loading rates 100-fold.

More... »

CT Approvals Down, Global Participation Up in Russia Q2

Wednesday, September 2, 2009 07:19 AM

According to an Orange Paper released by Russia-based CRO, Synergy Research Group, Russia’s health agency, the Federal Service on Surveillance in Healthcare and Social Development (RosZdraNadzor, RZN) approved only 129 new clinical trials, including local and bioequivalence studies, during Q2 2009, representing a 17% decrease from Q2 last year. The percentage of approved multinational clinical trials increased slightly, however, to 65% of the total during this time period.

More... »

Covance Finalizes Merck Deal, Delays Construction of Preclinical Unit

Thursday, August 20, 2009 06:35 AM

Covance officially closed a deal with Merck earlier this week to provide genomics analysis services to the drug developer for the next five years. Under the terms of the $145-million agreement, the contract research organization (CRO) acquired Merck’s Seattle-based Gene Expression Laboratory. All Merck employees related to the Seattle facility became Covance employees as of August 17.

More... »

PPD and Merck in Strategic Outsourcing Deal

Tuesday, January 6, 2009 11:25 AM

Contract research organization (CRO) PPD has entered into a strategic collaboration with Merck that will significantly expand PPD’s global central laboratory business.

More... »

Merck Report Could Alter Clinical Trials, Marketing

Monday, August 25, 2008 01:00 PM

A new report criticizing the use of seeding trials to drive pharmaceutical marketing efforts and jump-start sales could have far-reaching implications for pharmaceutical companies, research sites and clinical trials in general.

More... »

Merck's Isentress Results Positive

Friday, August 8, 2008 11:48 AM

Merck reported positive results from an ongoing phase II trial of Isentress for the treatment of HIV. This multi-center, dose-ranging, double-blind, randomized trial enrolled 198 treatment-naïve HIV-infected subjects.

More... »

Migraine Study Shows Merck's Telcagepant Promising

Monday, July 14, 2008 05:28 PM

Merck issued positive results from a phase III pivotal clinical trial of telcagepant, a calcitonin gene-related peptide (CGRP) antagonists for the treatment of migraine headaches. Merck stated the company plans to file for FDA approval in the U.S. in 2009.

More... »